Ottawa, ON (April 23, 2021) - Panakeia, the first THC-free (0.00%) and high CBG (18%) content hemp variety has been recently added by Health Canada on the List of Approved Cultivars (LOAC) for 2021. The variety named technically as HURV19PAN is the first THC-free and the first CBG variety approved by Health Canada, as well as the only CBG variety currently available in the country which it is distributed in Canada by Cannabis Orchards Inc, a biotechnology company based in Ottawa.
This list ensures the varieties are completely certified and THC levels are remaining under the prescribed level of less than 0.3% and this is easy for Panakeia with 0,00% THC.
“It is very humbling for our company, working in partnership with Hemp Trading in Spain, to introduce this breakthrough variety to Canada," Cannabis Orchard’s CEO Jamie Ghossein states. "Panakeia is the ideal candidate to lead a new and innovative Cannabis 3.0 wave in Canada, offering a new cannabinoid for consumers across the country. We are seeing very high demand, selling 30% of our production capacity in the first 48 hours since approval.”
“Panakeia is the only CBG variety currently approved by Health Canada. Motivated by the prospects of new therapeutic options for patients, we pride ourselves in finally offering CBG at industrial scale. This means new options for consumers, researchers, and patients across the country,” Ghossein confirms.
Cannabis Orchards is the first company to produce certified feminized industrial hemp seeds in Canada. Certified feminized seed for HURV19PAN will be available to industrial hemp and cannabis license holders in May 2021. Consumers can anticipate CBG products to hit the shelves in Q4 of 2021.
With 18% CBG and 0.00% THC, “Panakeia will be ground-breaking for the majority of cannabis users seeking health benefits and who are currently let down by the Canadian offering," Ghossein explains. "In fact, according to government data, we know most Canadians are using cannabis for medicinal purposes. Yet, the Canadian offering of medicinal cannabis varieties with high CBD or CBG content is very poor.
“At Cannabis Orchards, we are constantly conducting research in developing innovative varieties intended for medical benefit," Ghossein continues. "Through this partnership we know we can offer something new, not only to cannabis users but potentially to patients in hospital. We are seeking to conduct pre-clinical trials with this variety and others developed through our breeding program and private-public partnerships with Canadian Universities."
Higher benefits than CBD
Hemp Trading CEO, Ernesto Llosá, confirms that "CBG is the trend in the hemp market and Panakeia offers great economic benefits, much higher than CBD. In addition, this new variety surprises with harvests up to 4000 pounds per acre and cuts costs of purification in extractions, since it does not contain THC."
"For us, the Canadian market is key for commercializing Panakeia as hemp is grown here on a large scale similarly to the United States where Panakeia is being successfully distributed since more than one year ago," adds Llosá.
“Canada is believed to be the world’s No. 2 hemp producer behind China, though presently the majority is for grain and fiber,” Ghossein adds.
Panakeia is more than just CBG, it is a drastic shift for the hemp market – the ability to never fail a field compliance test, to transport all forms of the product from flower to concentrates, and to process with no need for THC remediation. In addition to these benefits, the high yields and flower quality of Panakeia are exceptional.
The potential of Panakeia not only lies in its 0.00% THC, but also in its high concentration of cannabigerol (CBG) up to 18%. Before Panakeia, CBG was present only in a residual way and now can provide extensive medicinal benefits, according to different studies. Research suggests that CBG may have beneficial effects in reducing pain, glaucoma or psoriasis; also it could have anti-inflammatory and antibacterial properties.
Panakeia is setting a new benchmark for pharmaceutical companies interested in exploring the medicinal properties of cannabis in a legal way.
Cannabis Orchards Inc is an innovative, research-driven biotechnology company focused on the production of innovative hemp varieties for their medicinal content. With a team of highly skilled physicians, plant breeders, agronomists, and biomedical scientists, Cannabis Orchards offers a complete package for cannabis-derived therapeutic development, from new variety development, feminized seed production, biomass cultivation, processing, to clinical application. Cannabis Orchards is responsible for the introduction of the first CBG variety to Canada. It is also the first company to produce certified feminized hemp seed in Canada. Led by a medical doctor, and with a focus on improving patient outcomes, Cannabis Orchards seeks to offer new therapeutic options and expand the body of research on minor cannabinoids. The novel materials they produce are highly sought after by licensed producers, licensed extraction facilities, and the pharmaceutical industry. Learn more at cannabisorchards.ca
Hemp Trading is a Spanish company with more than 15 years of experience distributing products for the cultivation of cannabis internationally. It currently operates in more than 20 countries in the EU, Latin America and the USA, making it one of the leaders in the cannabis market. Ever since it started operating, Hemp Trading, belonging to the same business group as Biomax, has focused on research and genetic improvements in cannabis. Thus, its team includes agronomy engineers and biotechnologists who apply the most sophisticated technologies, such as gas chromatography and genetic sequencing, to analyse the plants in terms of both their genotype and phenotype.
Hemp Trading aspires to become a global benchmark in the production of cannabis seeds that are high in medicinal phytocannabinoids. Therefore, the company is firmly committed to Research, Development and Innovation at the service of Premium THC-free genetics.